Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711689 | 1.00 | DRD2 (0.45) | DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL8155047 | 0.98 | — | — | |
| SCHEMBL31116785 | 0.90 | — | — | |
| SCHEMBL719940 | 0.90 | — | — | |
| SCHEMBL31116976 | 0.86 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL31116939 | 0.86 | — | — | |
| SCHEMBL31116758 | 0.86 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL31116802 | 0.84 | — | — | |
| SCHEMBL31116749 | 0.84 | DRD2 (0.40) | DRD2DRD3 | |
| SCHEMBL31116746 | 0.84 | HRH3 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795114-A | Novel iminonitrile derivative | 库拉德夫制药私人有限公司 | 2017-05-31 | — | — | CN | claimed |
| CN-103200936-B | Novel N-hydroxybenzamide compounds for the treatment of cancer | HOFFMANN LA ROCHE | 2015-03-11 | — | — | CN | claimed |
| CN-103200936-A | Novel N-hydroxybenzamide compounds for the treatment of cancer | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | claimed |
| EP-0442767-B1 | Method and apparatus for treating a natural gas | INST FRANCAIS DU PETROLE (FR) | 1994-07-20 | — | — | EP | claimed |
| CN-1041586-A | The preparation method of nitro-phenyl-dihydropyridine amides base | BAYER AG (DE) | 1990-04-25 | — | — | CN | claimed |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4428128-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| CN-118176185-A | 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application | 上海翰森生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20060258654-A1 | Pyridinylmorpholine derivatives | ELI LILLY AND COMPANY | 2006-11-16 | — | — | US | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005105763-A1 | SUBSTITUTED MORPHOLINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-11-03 | — | — | US | disclosed |
| CN-1252069-A | 5,6, 7-trisubstituted-4-aminopyrido [2, 3-d ] pyrimidine compounds | ABBOTT LAB (US) | 2000-05-03 | — | — | CN | disclosed |
| EP-0975633-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-02 | — | — | EP | disclosed |
| CN-1221417-A | Thiazolidinedione compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | REDDY RESEARCH FOUNDATION (IN) | 1999-06-30 | — | — | CN | disclosed |
| WO-1998046604-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051316-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TAAR1, TAAR5, AVPR2 | DRD2 171/4885DRD3 334/4885 |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | DRD2 4661/4885DRD3 4684/4885 |
| US-20050245519-A1 | Substituted morpholine compounds for the treatment of central nervous system disorders | CNR1, OPRM1, HCRTR1 | DRD2 47/4885DRD3 78/4885 |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | DRD2 4661/4885DRD3 4684/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | DRD2 4718/4885DRD3 4809/4885 |
| US-20060258654-A1 | Pyridinylmorpholine derivatives | OPRM1, OPRK1, CHRM1 | DRD2 75/4885DRD3 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.